Abrocitinib

Generic Name
Abrocitinib
Brand Names
Cibinqo
Drug Type
Small Molecule
Chemical Formula
C14H21N5O2S
CAS Number
1622902-68-4
Unique Ingredient Identifier
73SM5SF3OR
Background

Abrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). Janus kinases are intracellular enzymes involved in transduction pathways that regulate hematopoiesis and immune cell function. The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of aut...

Indication

Abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. In the US, it is indicated to treat refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inad...

Associated Conditions
Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, refractory Atopic dermatitis, Refractory, severe Atopic Dermatitis
Associated Therapies
-
Clinical Trials
Related News

A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

Phase 1
Completed
Conditions
Phase 1
Interventions
Drug: PF-04965842
Drug: Midazolam
First Posted Date
2018-08-27
Last Posted Date
2020-03-23
Lead Sponsor
Pfizer
Target Recruit Count
25
Registration Number
NCT03647670
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: PF-04965842
Other: rifampin
First Posted Date
2018-08-20
Last Posted Date
2020-02-28
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT03637790
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

A Hepatic Impairment Study for PF-04965842.

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
Drug: PF-04965842
First Posted Date
2018-08-13
Last Posted Date
2020-05-18
Lead Sponsor
Pfizer
Target Recruit Count
24
Registration Number
NCT03626415
Locations
🇺🇸

Prism Clinical Research, LLC, Saint Paul, Minnesota, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin

First Posted Date
2017-12-29
Last Posted Date
2019-10-14
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT03386279
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

Molecular Signatures in Inflammatory Skin Disease

First Posted Date
2017-11-30
Last Posted Date
2024-12-04
Lead Sponsor
Prof. Dr. Stephan Weidinger
Target Recruit Count
300
Registration Number
NCT03358693
Locations
🇩🇪

Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany

Absorption, Metabolism, Excretion and Absolute Bioavailability

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Absolute Bioavailability
Drug: PF-04965842
First Posted Date
2017-08-15
Last Posted Date
2017-12-21
Lead Sponsor
Pfizer
Target Recruit Count
6
Registration Number
NCT03250039
Locations
🇳🇱

PRA Health Sciences, Groningen, Netherlands

Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
Drug: PF-04965842
First Posted Date
2016-05-23
Last Posted Date
2019-05-02
Lead Sponsor
Pfizer
Target Recruit Count
269
Registration Number
NCT02780167
Locations
🇺🇸

The Dermatology Group, P.C, Verona, New Jersey, United States

🇺🇸

Dawes Fretzin Dermatology Group, LLC, Indianapolis, Indiana, United States

🇺🇸

Clinical Research Consortium, Las Vegas, Nevada, United States

and more 61 locations

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Phase 2
Terminated
Conditions
Plaque Psoriasis
Interventions
Other: Placebo
Drug: PF-04965842
First Posted Date
2014-07-28
Last Posted Date
2016-10-05
Lead Sponsor
Pfizer
Target Recruit Count
59
Registration Number
NCT02201524
Locations
🇺🇸

Northwest Arkansas Clinical Trials Center, PLLC/Hull Dermatology, PA, Rogers, Arkansas, United States

🇺🇸

California Dermatology & Clinical Research Institute, Encinitas, California, United States

🇺🇸

Clinical Science Institute, Santa Monica, California, United States

and more 42 locations

AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: PF-04965842
Drug: PF- 04965842
First Posted Date
2014-06-13
Last Posted Date
2014-08-18
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT02163161
Locations
🇧🇪

Pfizer Investigational Site, Brussels, Belgium

First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: PF-04965842
First Posted Date
2013-04-18
Last Posted Date
2014-06-20
Lead Sponsor
Pfizer
Target Recruit Count
79
Registration Number
NCT01835197
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy